Ahmed Alshawi, Haider Ali Alnaji
Ahmed Alshawi1*, Haider Ali Alnaji2
1Al-Furat Al-Awast Technical University, Kufa Institute, Medical Laboratory Department
2The Islamic University, College of Medical Technology, Medical Laboratory Department
Volume - 15,
Issue - 12,
Year - 2022
Type 2 diabetes is widely associated with dyslipidaemia in uncontrolled patients. Prediction parameters of cardiovascular diseases have controversial issue. Therefore, the aims of this study were to investigate i) the possibility of prediction of cardiovascular diseases (CVDs) from lipoprotein ratios (TG/HDL ratio, TC/HDL ratio) and/or non-HDL level ii) the role of TyG index in prediction of CVDs in uncontrolled DM. 107 participants were recruited in this study, 34 participants were DM (32%; control) and 73 participants were uncontrolled DM (68%). HbA1c, Fasting plasma glucose, lipid profile were measured. In this study the mean age of control DM group was (50.2±2.2), and (54.1±1.6) for uncontrolled group. Weight was higher in uncontrolled DM group. FPG and HbA1c were higher in uncontrolled group. Neither LDL-C nor LDL/HDL ratio showed a significant difference between controlled DM and Uncontrolled DM. TG/HDL was elevated in uncontrolled DM. non-HDL and TyG index were significantly increased in the uncontrolled group. We concluded that neither LDL-C nor LDL/HDL ratio have a predictive role for CVDs as proposed previously. TG/HDL ratio, non-HDL, and TyG index pointed out as a useful predictive parameters for CVDs in uncontrolled T2D.
Cite this article:
Ahmed Alshawi, Haider Ali Alnaji. TG/HDL, Non-HDL, and TyG index as predictive parameters for CVDs in uncontrolled diabetic patients better than LDL-C and LDL/HDL ratio. Research Journal of Pharmacy and Technology2022; 15(12):5490-4. doi: 10.52711/0974-360X.2022.00926
Ahmed Alshawi, Haider Ali Alnaji. TG/HDL, Non-HDL, and TyG index as predictive parameters for CVDs in uncontrolled diabetic patients better than LDL-C and LDL/HDL ratio. Research Journal of Pharmacy and Technology2022; 15(12):5490-4. doi: 10.52711/0974-360X.2022.00926 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-12-20
1. Kumbhar KP, Suryawanshi S, Patil SV. Novel route of inhaled insulin for diabetes treatment. Asian Journal of Pharmacy and Technology. 2022;12(1). doi.org/10.52711/2231-5713.2022.00005
2. Nizami SA, Ahmed VA, Marihal S. Simultaneous Spectrophotometric Analysis of Glimiperide, Metformin and Piogilitazone HCl in Combined Dosage Form. Research Journal of Pharmacy and Technology. 2010;3(2):518-21.
3. Prabavathy VJ, Sangeetha R. Stress Induced Type 2 Diabetes Mellitus among Industrial Workers–A Review. Research Journal of Pharmacy and Technology. 2019;12(1):396-402. doi.org/10.5958/0974-360X.2019.00072.6
4. Khalil K, Zrieki A. Factors associated with Glycemic control among Syrian patients with Type 2 Diabetes Mellitus. Age. 2022;30(40):40-50. doi.org/10.52711/0974-360X.2022.00285
5. Devi BL, Muthiah N, Murty K, Kumar S. Effects of 12 weeks Treatment with Conjugated Linoleic acid Supplementation on Body Fat Mass and Lipid Metabolism in Healthy, Obese Individuals-A Pilot Study. Research Journal of Pharmacy and Technology. 2018;11(3):996-1000. doi.org/10.5958/0974-360X.2018.00186.5
6. Sundarrajan T, Aanandhi V. Hypolipidemic Activity of Amaranthus Tristis Linn in Triton WR-1339 Induced Hyperlipidemic Rats. Group. 2017; 12:0.38. doi.org/10.5958/0974-360X.2017.00037.3
7. Kanthal L, Mondal P, Saha D, Mridha D, Mandal S. New Frontiers on Hyperlipidemia in Pharmaceutical Education. Research Journal of Pharmacology and Pharmacodynamics. 2010;2(4):257-60.
8. Alomar MJ, Al-Tabakha MM, Hussein ZA. Prediction model “T2DP” for the onset of Type 2 Diabetes Mellitus. Research Journal of Pharmacy and Technology. 2021;14(6):3325-32. doi.org/10.52711/0974-360X.2021.00578
9. Trautwein EA, McKay S. The role of specific components of a plant-based diet in management of dyslipidemia and the impact on cardiovascular risk. Nutrients. 2020;12(9):2671. doi.org/10.3390/nu12092671
10. Mach F, Baigent C, Catapano AL, Koskinas K, et al. ESC Scientific Document Group. 2019 ESC. EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and. 2020:111-88. doi.org/10.1093/eurheartj/ehz455
11. Kumar A, Lega S, Yadav SK. Spectral techniques for identification of triglycerides. Asian Journal of Research in Chemistry. 2017;10(5):708-10. DOI:10.5958/0974-4150.2017.00120.1
12. Nagabhushanam C, Devi ND, Vasu A, Rao D. A comparative randomized study of Guggulu and Atorvastatin Hypercholesterolemia patients. Research Journal of Pharmacology and Pharmacodynamics. 2010;2(2):187-9.
13. Jadhav KL, Kapare PR, Keskar CH, Shaikh F, Sawant S, Mali AS. Genetic insights of cholesterol and atherosclerosis; complex biology. Pharmacological and Pharmaceutical Reports. 2018;1(1):35-50.
14. Sugden M, Holness M. Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clinical Lipidology. 2011;6(4):401-11. https://doi.org/10.2217/clp.11.32
15. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clinical chemistry. 2010;56(6):977-86. https://doi.org/10.1373/clinchem.2009.142810
16. Korzun WJ, Nilsson G, Bachmann LM, Myers GL, Sakurabayashi I, Nakajima K, et al. Difference in bias approach for commutability assessment: application to frozen pools of human serum measured by 8 direct methods for HDL and LDL cholesterol. Clinical Chemistry. 2015;61(8):1107-13. https://doi.org/10.1373/clinchem.2015.240861
17. Bachorik P, Ross J. for the National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin Chem. 1995;41(10):1414-20. https://doi.org/10.1093/clinchem/41.10.1427
18. Rasouli M, Mokhtari H. Calculation of LDL‐Cholesterol vs. Direct Homogenous Assay. Journal of clinical laboratory analysis. 2017;31(3):e22057. https://doi.org/10.1002/jcla.22057
19. Choi R, Park M-J, Oh Y, Kim SH, Lee SG, Lee EH. Validation of multiple equations for estimating low-density lipoprotein cholesterol levels in Korean adults. Lipids in health and disease. 2021;20(1):1-11. https://doi.org/10.1186/s12944-021-01525-6
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18(6):499-502. https://doi.org/10.1093/clinchem/18.6.499
21. Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA cardiology. 2020;5(5):540-8. doi:10.1001/jamacardio.2020.0013
22. Hasegawa Y, Nakagami T, Oya J, Isago C, Kurita M, Tanaka Y, et al. Serum lipid management in patients with type 1 and type 2 diabetes: a hospital-based cohort study. Diabetology international. 2019;10(1):67-76. https://doi.org/10.1007/s13340-018-0365-z
23. Kearney P, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (London, England). 2008;371(9607):117-25. DOI: 10.1016/s0140-6736(08)60104-x
24. Shah AS, Urbina EM, Khoury PR, Kimball TR, Dolan LM. Lipids and lipoprotein ratios: contribution to carotid intima media thickness in adolescents and young adults with type 2 diabetes mellitus. Journal of clinical lipidology. 2013;7(5):441-5. https://doi.org/10.1016/j.jacl.2013.05.002
25. Hanak V, Munoz J, Teague J, Stanley Jr A, Bittner V. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. The American journal of cardiology. 2004;94(2):219-22. https://doi.org/10.1016/j.amjcard.2004.03.069
26. Katakami N, Kaneto H, Osonoi T, Saitou M, Takahara M, Sakamoto F, et al. Usefulness of lipoprotein ratios in assessing carotid atherosclerosis in Japanese type 2 diabetic patients. Atherosclerosis. 2011;214(2):442-7. https://doi.org/10.1016/j.atherosclerosis.2010.10.035
27. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes care. 2003;26(1):16-23. https://doi.org/10.2337/diacare.26.1.16
28. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non–HDL cholesterol, apolipoproteins AI and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. Jama. 2005;294(3):326-33. https://doi.org/10.1001/jama.294.3.326
29. Virani SS. Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Texas Heart Institute Journal. 2011;38(2):160. PMID: 21494527
30. Louter L, Visseren F, Roeters van Lennep J. A fasting lipid profile is not a necessity in majority of cases. Nederlands Tijdschrift Voor Geneeskunde. 2020;164. PMID: 32608924
31. da Silva A, Caldas APS, Hermsdorff HHM, Bersch-Ferreira ÂC, Torreglosa CR, Weber B, et al. Triglyceride-glucose index is associated with symptomatic coronary artery disease in patients in secondary care. Cardiovascular diabetology. 2019;18(1):1-8. https://doi.org/10.1186/s12933-019-0893-2
32. Verma AK, Dubey G, Agrawal A. Biochemical studies on serum Hb, Sugar, Urea and lipid profile under influence of ocimum sanctum L in aged patients. Research Journal of Pharmacy and Technology. 2012;5(6):791.
33. Soni S, Soni A, Ganatra S. Studies on the Optimum Reaction Time for Commercial Cholesterol kits. Asian Journal of Research in Chemistry. 2013;6(10):950-1.
34. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Annals of internal medicine. 1994;121(9):641-7. https://doi.org/10.7326/0003-4819-121-9-199411010-00002
35. Control CfD, Prevention. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol—United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60(4):109-14. PubMed ID 21293326
36. Hanefeld M, Traylor L, Gao L, Landgraf W. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL. Cardiovascular Diabetology. 2017;16(1):1-9. https://doi.org/10.1186/s12933-017-0548-0
37. Parhofer KG, Laubach E, Barrett PHR. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. Journal of lipid research. 2003;44(6):1192-8. https://doi.org/10.1194/jlr.M300011-JLR200
38. Taskinen M-R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46(6):733-49. https://doi.org/10.1007/s00125-003-1111-y
39. Wang W, Khan S, Blackett P, Alaupovic P, Lee E. Apolipoproteins AI, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes. Journal of clinical lipidology. 2013;7(1):38-42. https://doi.org/10.1016/j.jacl.2012.06.007